Iritis-UveitisMANAGEMENT

OPHTHALMOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

644 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Acute angle-closure glaucoma Central retinal artery occlusion Central Retinal Vein Occlusion Chemical eye injury Corneal abrasion Corneal ulcer Endophthalmitis Globe rupture Herpes zoster ophthalmicus Hyphema Iritis-Uveitis Ocular foreign body Optic Neuritis Orbital cellulitis Orbital Floor Fracture (Blowout)Posterior vitreous detachment Retinal detachment Retrobulbar hematoma and orbital compartment syndrome Vitreous Hemorrhage

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp50

Immediate priorities

›Vision-threatening emergencies

›Acute angle-closure glaucoma exclusion

›Mid-dilated fixed pupil vs. miotic pupil of iritis

›Rock-hard globe on palpation

›Nausea and vomiting with severe ocular pain

›Endophthalmitis exclusion

›Hypopyon with systemic sepsis signs

›Post-surgical or penetrating injury history

›Severe vision loss disproportionate to clinical findings

›If endophthalmitis suspected, emergent ophthalmology consult and IV antibiotics

›Vancomycin 1 g IV plus ceftazidime 2 g IV empirically

›Do not delay for imaging

›Stabilization priorities

›Visual acuity documentation in both eyes

›Snellen chart or finger counting

›Pinhole acuity to estimate refractive vs. structural deficit

›Intraocular pressure measurement

›Tonometry if available

›Elevated IOP suggests glaucoma or steroid response

›Decreased IOP suggests ciliary body shutdown from severe inflammation

›Slit-lamp availability triage

›If slit lamp unavailable, clinical diagnosis based on consensual photophobia and circumcorneal injection

›Ophthalmology referral for all cases

Monitoring and targets

›Clinical monitoring bundle

›Serial visual acuity

›Document at presentation and reassessment

02History/hx80

Presenting symptoms

›Pain characteristics

›Deep aching ocular pain

›Worsened by bright light and accommodation

›Sharp and photophobic quality

›Consensual photophobia

›Pain in affected eye when light shone in contralateral eye

›Pathognomonic for ciliary spasm

›Onset and laterality

›Acute onset more typical of HLA-B27-associated and idiopathic

›Insidious onset raises concern for granulomatous or chronic etiologies

›Unilateral vs. bilateral — bilateral raises systemic disease likelihood

›Visual symptoms

›Blurred vision

›Present in up to 50% of anterior uveitis cases

›Floaters or visual distortion

›Suggests intermediate or posterior segment involvement

›Halos around lights

›Raises concern for angle-closure glaucoma as mimicker

Symptom timeline and prior episodes

›Episode history

›Recurrent iritis

›Common pattern — frequency and prior workup

›Recurrence without systemic diagnosis warrants rheumatologic evaluation

›Duration of current episode

›Acute: less than 3 months; chronic: 3 months or greater

›Prior treatments and response

›Topical steroid use, taper schedule, and compliance

Associated systemic symptoms

›Musculoskeletal

›Low back pain and morning stiffness

›Ankylosing spondylitis or axial spondyloarthritis

›HLA-B27 positivity in up to 50% of anterior uveitis cases

›Joint swelling

›Reactive arthritis, psoriatic arthritis, IBD-associated arthritis

›Dermatologic

›Psoriatic plaques

›Erythema nodosum

›Oral or genital ulcers — Behcet disease

›Vesicular rash on face or eyelid — HSV or VZV

›Vitiligo or poliosis — Vogt-Koyanagi-Harada syndrome

›Pulmonary

›Cough or dyspnea — sarcoidosis or TB

›Gastrointestinal

›Chronic diarrhea or bloody stools — IBD

›Neurologic

›Headache, tinnitus, hearing loss — VKH syndrome

›Numbness or weakness — MS-associated uveitis

›Genitourinary

›Urethritis or dysuria — reactive arthritis

›Recent STI exposure — syphilis-associated uveitis

›Constitutional

›Fever, night sweats, weight loss — TB, lymphoma, sarcoidosis

Risk factors and exposures

›Genetic and demographic risk

›HLA-B27 positivity

›Strongest genetic risk factor for acute anterior uveitis

›Associated with axial spondyloarthritis in 15% to 50% of anterior uveitis cases

›Age 20 to 50 years

›60% to 80% of cases occur in this range

›Male sex

›HLA-B27-associated uveitis more common in men (male:female ratio up to 1.5:1)

›Autoimmune comorbidities

›Spondyloarthritis, psoriatic arthritis, IBD, sarcoidosis

›Behcet disease, MS, juvenile idiopathic arthritis

›Infectious risk

›HSV or VZV — 5% to 15% of uveitis cases

›TB — 1% to 13%

›Syphilis — 1% to 4%; rising rates in MSM

›Toxoplasmosis — 5% to 7%

›HIV status and immunocompromise — CMV retinitis risk

›Medication history

›Immune checkpoint inhibitors — nivolumab, pembrolizumab

›Bisphosphonates — pamidronate, alendronate

›Rifabutin

›Fluoroquinolones — moxifloxacin

›Sulfonamides, topiramate, latanoprost

›Trauma history

›Recent blunt ocular trauma — traumatic iridocyclitis

›Recent ocular surgery — exogenous endophthalmitis must be excluded

›Geographic and social history

›Travel to endemic TB or Behcet regions (Silk Road)

›IV drug use — endogenous endophthalmitis risk

›MSM status — ocular syphilis rates rising

03Physical Exam/exam53

Ocular examination

›Visual acuity

›Decreased in up to 50% of anterior uveitis cases

›Document each eye separately

›Severe reduction suggests posterior involvement or complication

›Pupillary assessment

›Miotic (constricted) and sluggishly reactive pupil

›Ciliary muscle spasm mechanism

›Irregular pupil shape

›Posterior synechiae causing iris-lens adhesions

›Mid-dilated fixed pupil

›Suggests acute angle-closure glaucoma — not iritis

›Injection pattern

›Circumcorneal (perilimbal) injection

›Redness concentrated around the limbus

›Distinct from diffuse injection of conjunctivitis

›Ciliary flush

›Deep violaceous ring around cornea

Anterior segment findings

›Anterior chamber

›Cells and flare on slit lamp — gold standard finding

›Cells: white blood cells suspended in aqueous humor

›Flare: protein leakage giving Tyndall beam effect

›Hypopyon

›Layered white or yellow material in inferior anterior chamber

›Visible without slit lamp in severe cases

›Suggests severe inflammation or endophthalmitis

›Keratic precipitates

04Differential Diagnosis/ddx51

Cannot-miss diagnoses

›Acute angle-closure glaucoma

›ICD-10: H40.21

›Severe pain, halos around lights, nausea and vomiting

›Mid-dilated fixed pupil vs. miotic pupil of iritis

›Rock-hard globe on palpation

›Immediate ophthalmology referral required

›Endophthalmitis

›ICD-10: H44.0

›Post-surgical or penetrating injury history

›Hypopyon, severe vision loss, systemic sepsis signs

›Emergent IV antibiotics and vitrectomy consideration

›Keratitis

›ICD-10: H16

›Bacterial or herpetic — corneal opacity, fluorescein staining positive

›Dendritic ulcer pattern pathognomonic for HSV

›Ocular lymphoma (masquerade syndrome)

›ICD-10: C85.9

›Consider in patients over 50 with chronic uveitis refractory to steroids

›Accounts for 1% to 5% of uveitis cases

Common mimics

›Conjunctivitis

›ICD-10: H10

›Diffuse injection, discharge, no significant photophobia

›Pain relieved by topical anesthetic

›No anterior chamber cells on slit lamp

›Episcleritis

›ICD-10: H15.1

05Laboratory Tests/lt38

First-episode uncomplicated anterior uveitis

›Lab workup indication

›No labs required for first episode of unilateral, non-granulomatous anterior uveitis in a young adult without systemic symptoms

›JAMA 2025 guideline-concordant approach

›Clinical diagnosis is sufficient in this context

›Defer workup to ophthalmology follow-up visit

Recurrent, bilateral, or atypical presentations

›Infectious serology

›RPR/VDRL and FTA-ABS (syphilis)

›Recommended in all forms of non-idiopathic uveitis

›Rising ocular syphilis rates necessitate routine screening

›QuantiFERON-TB Gold or tuberculin skin test

›Most contributive first-step investigation — 17.1% diagnostic yield in ULISSE study

›HIV testing in at-risk populations

›CMV retinitis and atypical infections in immunosuppressed

›Inflammatory and autoimmune markers

›HLA-B27

›Positive in 56% of tested acute anterior non-granulomatous uveitis cases (ULISSE study)

›Most contributive test in this subgroup

›ACE level

›Elevated in sarcoidosis — sensitivity 57%, specificity 90%

›CBC, ESR, CRP

›Nonspecific; helpful for systemic inflammation burden

›ANA panel

›Juvenile idiopathic arthritis-associated uveitis in pediatric patients

›Renal and metabolic

›Urinalysis

›Tubulointerstitial nephritis and uveitis (TINU) syndrome

06Diagnostic Tests/dt61

Scoring Systems

›Standardized Uveitis Nomenclature (SUN) grading

›Anterior chamber cell grading

›0: less than 1 cell per field

›0.5+: 1 to 5 cells

›1+: 6 to 15 cells

›2+: 16 to 25 cells

›3+: 26 to 50 cells

›4+: greater than 50 cells

›Anterior chamber flare grading

›0: none

›1+: faint

›2+: moderate (iris and lens detail clear)

›3+: marked (iris and lens detail hazy)

›4+: intense (fixed coagulated fibrin)

›SUN anatomic classification

›Anterior: between anterior limiting lamina of vitreous and corneal endothelium

›Intermediate: vitreous and pars plana

›Posterior: choroid and retina

›Panuveitis: all segments

MRI

›Sacroiliac joint MRI

›Indications

›Suspected ankylosing spondylitis or axial spondyloarthritis

›Chronic low back pain with HLA-B27 positivity

›46.4% diagnostic yield when clinically indicated (ULISSE study)

›Findings

›Bone marrow edema at SI joints

07Disposition/dispo26

Discharge criteria

›Uncomplicated anterior uveitis discharge

›First-episode or known recurrent anterior uveitis

›Vision preserved (20/40 or better)

›No hypopyon

›No posterior segment involvement

›Discharge with topical steroids and cycloplegics

›Ophthalmology follow-up within 24 to 48 hours mandatory

›Return precautions provided

Same-day ophthalmology referral

›Urgent referral indications

›Vision loss or distortion with eye pain and redness

›Hypopyon visible

›Suspected posterior segment involvement (floaters, visual distortion)

›Recurrent or bilateral disease

›Herpetic vesicles on eyelid or face

Emergency department referral or admission

›Admission indications

›Systemic illness with ocular symptoms

›Fever, hypotension, altered mental status — endophthalmitis or sepsis concern

›Suspected endogenous endophthalmitis

›IV antibiotics and possible vitrectomy

›Severe vision loss with uncertain diagnosis

Follow-up planning

›Post-discharge follow-up

›24 to 48 hours with ophthalmology for slit-lamp reassessment

›Confirm diagnosis and adjust steroid frequency

›1 week for steroid taper assessment

08Treatment/t71

Topical corticosteroids

›Prednisolone acetate 1%

›First-line topical corticosteroid for anterior uveitis

›Severe disease: 1 drop every 1 hour while awake

›Mild to moderate disease: 1 drop every 4 hours

›Taper schedule (ophthalmology-directed)

›Reduce by 1 drop per day per week

›Example: q1h to 6x/day to 5x/day to 4x/day

›Individualize to clinical response and SUN grading

›Shake bottle well before each use (suspension)

›Difluprednate 0.05%

›Alternative to prednisolone acetate

›1 drop 4 times daily

›Noninferior to prednisolone acetate 8x daily (Sheppard 2014, Phase III RCT)

›Higher IOP elevation risk vs. prednisolone

›Increased IOP monitoring recommended

›Benefit: less frequent dosing improves adherence

Cycloplegic agents

›Cyclopentolate 1%

›Preferred agent for mild to moderate iritis

›1 drop 3 times daily

›Duration of action 6 to 24 hours

›Mechanism: ciliary muscle paralysis

›Relieves ciliary spasm and pain

›Prevents posterior synechiae formation

›Homatropine 5%

›Alternative cycloplegic

›1 drop 3 times daily

›Duration of action 24 to 72 hours

›Atropine 1%

›Reserved for severe iritis

›1 drop twice daily

›Duration of action 7 to 14 days

›Use with caution — prolonged mydriasis and systemic absorption risk

›Cycloplegic cautions

›Avoid if concern for elevated IOP or narrow angle

›Systemic absorption can cause tachycardia, dry mouth, urinary retention

Systemic corticosteroids

›Oral prednisone

›Indications

›Topical drops unavailable or disease worsening despite topical therapy

›Bilateral severe anterior uveitis

›Dosing: 40 to 60 mg daily

›Taper over 4 to 6 weeks guided by ophthalmology

›Contraindications

›Uncontrolled diabetes, severe osteoporosis, active infection

Infectious uveitis treatment

›Herpetic uveitis (HSV/VZV)

›Antiviral therapy required before or concurrent with steroids

›Acyclovir 400 mg orally 5 times daily for 7 to 10 days

›Valacyclovir 1 g orally 3 times daily as alternative

›Topical NSAID (e.g., ketorolac) if steroids must be withheld pending antiviral coverage

›Syphilitic uveitis

›IV benzylpenicillin G 3 to 4 million units every 4 hours for 10 to 14 days

›Neurosyphilis protocol applies to all ocular syphilis

›Allergy: doxycycline 100 mg twice daily for 28 days (limited evidence)

›Toxoplasma uveitis

›Pyrimethamine 100 mg loading then 25 to 50 mg daily plus sulfadiazine 1 g 4 times daily plus folinic acid 10 to 15 mg daily

›Alternative: trimethoprim-sulfamethoxazole 160/800 mg twice daily

›TB uveitis

›Standard 4-drug anti-TB regimen in consultation with infectious disease

IOP management

›Elevated IOP in the setting of uveitis

›Topical beta-blocker: timolol 0.5%, 1 drop twice daily

›First-line for acute IOP elevation

›Topical carbonic anhydrase inhibitor: dorzolamide 2%, 1 drop 3 times daily

›Prostaglandin analogues: avoid in active uveitis — may worsen inflammation

Refractory and chronic uveitis

›Sub-Tenon or intravitreal corticosteroid injections

›For inadequate response to topical therapy

›Triamcinolone acetonide 40 mg/mL sub-Tenon injection

›Systemic immunosuppression (ophthalmology and rheumatology directed)

›Methotrexate 7.5 to 25 mg weekly — first-line steroid-sparing agent

›Mycophenolate mofetil 1 to 1.5 g twice daily

›Adalimumab (anti-TNF) — FDA approved for non-infectious intermediate, posterior, and panuveitis

›80 mg SC loading, then 40 mg SC every 2 weeks

›Infliximab for refractory Behcet uveitis

09Special Populations/sp72

Pregnancy

›Physiologic considerations

›Immune modulation in pregnancy may alter uveitis activity

›Disease may improve in second and third trimester

›Flares more common postpartum

›Many systemic immunosuppressants contraindicated in pregnancy

›Methotrexate — Category X; absolutely contraindicated

›Mycophenolate — Category D; contraindicated

›Medication safety in pregnancy

›Topical prednisolone acetate 1%

›Preferred — minimal systemic absorption

›Monitor for gestational hypertension with prolonged use

›Cycloplegics

›Short-term use generally considered safe

›Atropine — avoid prolonged use due to systemic absorption

›Systemic prednisone

›Low-dose acceptable for short-term use

›Association with gestational diabetes and hypertension

›Cyclosporine A

›Relatively safe in pregnancy for refractory disease

›Monitor renal function and blood pressure

›Antiviral treatment in pregnancy

›Acyclovir — Category B, generally safe for herpetic uveitis

›Avoid high-dose systemic antifungals if fungal etiology

›Delivery planning

›Coordinate with ophthalmology for active uveitis at time of delivery

›Immunosuppressant discontinuation timing with obstetrics

Geriatric

›Epidemiology in elderly

›Uveitis presentation in patients over 60 warrants higher suspicion for masquerade syndromes

›Intraocular lymphoma in 1% to 5% of uveitis cases

›Metastatic disease

›Herpetic uveitis more common with advanced age and immunosenescence

›Medication considerations

›Topical steroids

›Higher risk of steroid-induced IOP elevation

›IOP monitoring more frequent (every 1 to 2 weeks initially)

›Cycloplegics

›Urinary retention risk — monitor particularly with atropine

›Anticholinergic burden — caution in cognitive impairment

›Systemic corticosteroids

›Higher risk of vertebral fractures, hyperglycemia, hypertension

›Calcium 1000 to 1200 mg and vitamin D 800 IU daily supplementation

›Systemic immunosuppressants

›Reduced renal clearance affects methotrexate and mycophenolate dosing

›Monthly CBC and LFTs during methotrexate therapy

›Comorbidity interactions

›Pre-existing glaucoma and cataract common — steroid use requires careful monitoring

›Dry eye disease may complicate topical drop tolerability

Pediatrics

›Juvenile idiopathic arthritis-associated uveitis

›Most common systemic cause of uveitis in children

›Oligoarticular JIA — highest uveitis risk (30% of cases)

›ANA positivity associated with uveitis risk

›Typically chronic, insidious, and asymptomatic

›Screening slit-lamp exams required every 3 to 6 months in at-risk JIA patients

›Risk of band keratopathy, cataract, and glaucoma

›Medication safety in pediatrics

›Topical prednisolone acetate 1%

›Safe at standard dosing; monitor IOP

›Cycloplegics

›Cyclopentolate 1% preferred — shorter duration

›Atropine 0.5% in younger children; monitor for systemic toxicity (fever, flushing, tachycardia)

›Methotrexate

›10 to 15 mg/m2 weekly — first-line steroid-sparing agent in JIA-associated uveitis

›Adalimumab

›Approved for pediatric non-infectious uveitis

›Dosing: 20 mg SC every 2 weeks for weight under 30 kg; 40 mg SC every 2 weeks for 30 kg or greater

›Pars planitis

›Intermediate uveitis common in pediatric population

›Associated with MS in up to 15% of cases in older children

›Snowball vitreous opacities and snowbank deposits

›Toxocara and toxoplasma

›Common infectious causes of pediatric posterior uveitis

›Serologic testing in granulomatous or posterior presentations

10Background/b69

Epidemiology

›Prevalence and incidence

›Uveitis prevalence approximately 38 to 714 per 100,000 population

›Anterior uveitis accounts for 41% to 60% of all uveitis cases

›Annual incidence approximately 17 to 52 per 100,000

›Leading cause of preventable blindness in working-age adults

›Accounts for 10% to 15% of total blindness in developed countries

›Demographics

›Peak incidence age 20 to 50 years (60% to 80% of cases)

›HLA-B27-associated uveitis male predominance (ratio up to 1.5:1)

›JIA-associated uveitis predominantly female (3:1)

›Etiology distribution

›Idiopathic — 27% to 51% of cases

›HLA-B27-associated — 15% to 50% of anterior uveitis cases

›Infectious — HSV/VZV (5%-15%), TB (1%-13%), syphilis (1%-4%), toxoplasma (5%-7%)

›Masquerade syndromes — 1% to 5%

›Geographic variation

›Behcet disease more common along Silk Road (Turkey, Middle East, Central Asia)

›TB-associated uveitis more prevalent in low and middle-income countries

›Environmental risk factors include air pollution and tobacco smoking

Pathophysiology

›Inflammatory cascade

›Breakdown of blood-aqueous barrier

›Tight junction disruption in ciliary body and iris vasculature

›Protein and cellular exudation into aqueous humor (flare and cells)

›T-cell mediated inflammation

›CD4+ Th1 and Th17 cells predominate in HLA-B27-associated uveitis

›TNF-alpha, IL-6, and IL-17 drive inflammation

›Molecular mimicry hypothesis

›HLA-B27 may present bacterial antigens cross-reactive with ocular self-antigens

›HLA-B27 mechanism

›HLA-B27 is a class I major histocompatibility complex molecule

›Aberrant folding can trigger UPR (unfolded protein response) and NLRP3 inflammasome activation

›Dysregulation of innate and adaptive immunity in intestine and joint

›Complications of untreated inflammation

›Posterior synechiae

›Iris-lens adhesions from fibrinous exudate

›Can cause pupillary block and secondary glaucoma

›Cataract formation

›Chronic inflammation and steroid exposure

›Macular edema

›Most common cause of visual loss

›Cystoid macular edema detectable on OCT

›Secondary glaucoma

›Trabecular meshwork obstruction by inflammatory cells

Therapeutic Considerations

›Corticosteroid therapy rationale

›Anti-inflammatory mechanism

›Stabilizes blood-aqueous barrier

›Suppresses cytokine release and cellular infiltration

›Topical route preferred for anterior uveitis

›High intraocular bioavailability with prednisolone acetate 1%

›Suspension requires shaking for uniform dosing

›Risks of chronic steroid use

›Steroid-induced glaucoma (IOP rise in 30% to 40% of patients)

›Posterior subcapsular cataract with prolonged use

›Cycloplegic rationale

›Ciliary body paralysis

›Eliminates painful ciliary muscle spasm

›Stabilizes blood-aqueous barrier by reducing uveal blood flow

›Synechiae prevention

›Dilated pupil prevents iris-lens contact and adhesion

›Steroid-sparing rationale for chronic disease

›Chronic uveitis requires long-term immunosuppression

›Topical steroids inadequate for posterior or intermediate disease

›Systemic agents target upstream inflammatory pathways

›Anti-TNF therapy (adalimumab) — Class I recommendation for non-infectious uveitis

›Reduces uveitis flares and steroid burden in chronic disease

›Key treatment principle

›Infectious etiologies must be excluded or treated before initiating immunosuppression

›Steroids without antiviral coverage worsens herpetic uveitis

›TB must be treated before anti-TNF therapy to prevent reactivation

11Patient Discharge Instructions/pdi33

copy discharge instructions

›Diagnosis and overview

›You have been diagnosed with iritis (inflammation inside the eye)

›This is a condition where the inside of your eye is inflamed and needs treatment

›With proper treatment, most cases improve within 4 to 6 weeks

›Your medications

›Eye drops — topical steroid

›Shake the prednisolone bottle well before each use (it is a suspension)

›Use as directed — do not skip doses or stop without medical advice

›Do NOT stop steroid drops abruptly — must be tapered to prevent rebound

›Eye drops — dilating drops (cycloplegic)

›These widen your pupil to relieve pain and prevent scarring inside the eye

›Your vision will be blurry and you will be sensitive to light — this is expected

›Do not drive if your vision is significantly blurred

›Follow-up

›Urgent ophthalmology (eye doctor) appointment required within 24 to 48 hours

›Do not skip this appointment — your eye needs to be checked with a slit lamp

›Continue all prescribed drops until instructed otherwise by your eye doctor

›Comfort measures

›Wear sunglasses outdoors — bright light will be very uncomfortable

›Avoid rubbing your eye

›Avoid contact lens use until cleared by your ophthalmologist

›Return to emergency department immediately for

›Worsening eye pain or sudden severe headache

›Significant loss of vision or new visual distortion

›Increasing redness despite using the drops for 48 hours

›Development of fever or feeling generally unwell

›New symptoms in the other eye

12References/r40

Guidelines and key sources

›Maghsoudlou P, Epps SJ, Guly CM, Dick AD

›Uveitis in Adults

›JAMA 2025

›Primary evidence source for clinical presentation, epidemiology, and management

›Angulo MI, Barajas M, Vela M

›What Is Uveitis?

›JAMA 2025

›Patient-oriented overview and diagnostic algorithm

›Burkholder BM, Jabs DA

›Uveitis for the Non-Ophthalmologist

›BMJ 2021

›Practical diagnostic and management framework for non-specialists

›Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS

›Difluprednate 0.05% Versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: A Phase III, Multicenter, Randomized Study

›Investigative Ophthalmology and Visual Science 2014

›Evidence for difluprednate noninferior dosing

›Grumet P, Kodjikian L, de Parisot A, et al

›Contribution of Diagnostic Tests for the Etiological Assessment of Uveitis: ULISSE Study

›Autoimmunity Reviews 2018

›Diagnostic yield data for HLA-B27, QuantiFERON-TB, CXR

›Seve P, Cacoub P, Bodaghi B, et al

›Uveitis: Diagnostic Work-Up — Literature Review and Expert Committee Recommendations

›Autoimmunity Reviews 2017

›Expert committee diagnostic workup guidelines

›Leibowitz HM

›The Red Eye

›New England Journal of Medicine 2000

Learn More: Iritis-Uveitis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.